

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

NEOTHERAPEUTICS INC
Form 8-K
April 29, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934

April 29, 2002
Date of Report (Date of earliest event reported)

NEOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

| | | |
|---|---------------------------------------|---|
| DELAWARE (State or other Jurisdiction of Incorporation) | 000-28782 (Commission File Number) | 93-0979187 (IRS Employer Identification Number) |
|---|---------------------------------------|---|

| | |
|--|---------------------|
| 157 TECHNOLOGY DRIVE IRVINE, CALIFORNIA (Address of principal executive offices) | 92618 (Zip Code) |
|--|---------------------|

(949) 788-6700
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS.

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

On April 29, 2002, NeoTherapeutics, Inc. issued a news release announcing the preliminary results of the Company's recently completed clinical trial of Neotrofin(TM) in Alzheimer's disease. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

ITEM 7. EXHIBITS

Exhibits:

99.1 Press Release dated April 29, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: April 29, 2002

By: /s/ Samuel Gulko

Name: Samuel Gulko
Title: Senior Vice President Finance,
Chief Financial Officer,
Secretary and Treasurer

| Exhibit Number ----- | Document Description ----- |
|----------------------------|------------------------------------|
| 99.1 | Press Release dated April 29, 2002 |